ExcellGene SA

ExcellGene SA is a Swiss biotechnology startup specializing in providing cell line development and protein expression services. With over 20 years of experience, the company offers high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). ExcellGene SA has a proven track record in expressing various types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, and cytokines. The company's team of scientists provides comprehensive support, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. ExcellGene SA prides itself on its commitment to quality and customer satisfaction, positioning itself as a trusted partner in cell line and process development. With its headquarters in Switzerland and founded in 2001, the company presents a promising opportunity for venture capitalists looking to invest in the biotechnology and information technology industries.

Overall, ExcellGene SA presents a compelling opportunity in the biotechnology field, with its robust track record and specialized services making it an attractive investment prospect. With its focus on quality and experience in cell line development, ExcellGene SA stands out as a potential investment opportunity for venture capitalists interested in the biotechnology and IT sectors.